Previous session Next session

Drug and alcohol treatment

Networking zone 1 (N1)

In programme

Thursday, 24 November, 2022 - 15:00 to 16:30

View presentations

About

This session explores a number of present-day alcohol and drug pharmacological and other treatment issues. The wide-ranging presentations cover Naloxone, Buprenorphine and pharmacological methamphetamine treatments. There are also presentations about treatment outcome measures and evaluation approaches.

Consult all e-posters >>

Chair

Research director,
Finnish Foundation for Alcohol Studies,
Finland

Type

e-poster guided tour

Tracks

Open track

Keywords

Presentations

Thursday, 24 November

15:00

Characterising the neurobiology of detoxification in opiate dependence: is there a role for NK1 antagonism to improve outcomes?

Networking zone 1 (N1)

Katherine Herlinger

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up

Networking zone 1 (N1)

Medically supervised opioid withdrawal treatment: is it possible to predict the successful outcome?

Networking zone 1 (N1)

Artūras Barkus

Outcome measurement and evaluation as a routine practice in alcohol and other drug services in Belgium (OMER-BE)

Networking zone 1 (N1)

Patient-reported outcomes of subcutaneous depot buprenorphine treatment in Australian correctional centres

Networking zone 1 (N1)

Psychostimulant-induced neuroinflammation: the protective role of IL-10

Networking zone 1 (N1)

Ana Isabel Silva

Real-world effectiveness of various pharmacological treatments in methamphetamine/amphetamine use disorders

Networking zone 1 (N1)

Milja Heikkinen

Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial

Networking zone 1 (N1)

Starting Buprenorphine therapy. Challenges and difficulties

Networking zone 1 (N1)

Esmeralda Thoma

Previous session View the programme Next session